Highest-materiality recent filing
MacroGenics completes $122.5M sale of GMP manufacturing to Bora Pharmaceuticals
Closed sale of GMP manufacturing (CDMO) to Bora Pharmaceuticals for $122.5M cash, subject to post-closing adjustments.
MacroGenics reports Q1 loss, divests manufacturing, extends cash runway through 2028
Manufacturing operations sold to Bora Pharmaceuticals for $122.5M upfront; expected to close Q3 2026.
MacroGenics sells GMP manufacturing operations to Bora Pharma for $122.5M upfront
Bora pays $122.5M cash at closing for MacroGenics' CDMO business, including Rockville site (11,000 L capacity) and Frederick warehouse.
MacroGenics receives additional $60M from Sagard in amended ZYNYZ royalty deal
Received $60M cash from Sagard, bringing aggregate royalty purchase price to $130M.
FDA removes partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab
FDA lifted partial clinical hold on Phase 2 LINNET study of lorigerlimab (bispecific DART targeting PD-1 and CTLA-4).
MacroGenics reports FY2025 net loss of $74.6M, cash $189.9M; pipeline data catalysts for 2026
Net loss $74.6M in 2025 vs $66.9M in 2024; revenue flat at $149.5M; cash $189.9M down from $201.7M.
Partial hold halts new enrollment; current participants may continue receiving lorigerlimab.
CMO Stephen Eck Departs MacroGenics; Frank Perabo Named Interim Lead
Stephen Eck, SVP Clinical Development and CMO, to depart MacroGenics effective Dec 31, 2025 by mutual agreement.
Net income $16.8M ($0.27 diluted EPS) vs $56.3M ($0.90) in Q3 2024; revenue $72.8M down from $110.7M.
MacroGenics Q2 2025 net loss $36.3M; new CEO Eric Risser outlines strategic priorities
Cash, equivalents and marketables $176.5M as of June 30, 2025; cash runway through first half 2027.
MacroGenics appoints Eric Risser as President and CEO, succeeding Scott Koenig
Eric Risser, previously COO since 2022, becomes CEO and Class I director effective Aug 13, 2025.
MacroGenics sells ZYNYZ royalty rights to Sagard for $70M; cash runway extended into H1 2027
Received $70M upfront from Sagard for capped royalty on global net sales of ZYNYZ (retifanlimab-dlwr).
MacroGenics Q1 2025 net loss improves to $41M; cash runway into H2 2026
Net loss of $41.0M ($0.65 loss per share) vs Q1 2024 loss of $52.2M ($0.84).
MacroGenics reports FY2024 net loss of $67M; discontinues vobra duo development
Net loss of $67.0M ($1.07 diluted EPS) for FY2024 vs. net loss of $9.1M ($0.15) in FY2023.
MacroGenics amends CEO Scott Koenig's separation agreement; departure date extended indefinitely
Amendment extends CEO Scott Koenig's separation date beyond original Feb 28, 2025; Board will set new date with 14 days notice.
MacroGenics Q3 net income $56.3M; cash runway into 2026; MARGENZA sale progress
Net income $56.3M ($0.90 diluted EPS) vs $17.6M in Q3 2023; revenue $110.7M driven by $100M Incyte milestone.
MacroGenics CEO Scott Koenig to step down; search committee formed
Scott Koenig to depart as President and CEO effective Feb 28, 2025; will resign from Board on same date.
6-month radiographic PFS rate 69% (2.0 mg/kg) and 70% (2.7 mg/kg); median rPFS ~8.5 and 7.5 months (immature).
MacroGenics Q2 net loss $55.7M; receives $100M Incyte milestone
Net loss of $55.7M ($0.89 diluted EPS) vs net income of $57.5M in Q2 2023.
MacroGenics receives $100M milestone payment from Incyte for retifanlimab collaboration
MacroGenics and Incyte amended their 2017 collaboration agreement, deeming milestones achieved and triggering a $100M payment to MacroGenics.
IDMC recommended stopping dosing for remaining participants; most had received 8-12 cycles.
MacroGenics Q1 net loss $52.2M; interim TAMARACK data shows vobra duo activity in mCRPC
Q1 net loss $52.2M ($0.84/share) vs $38.0M loss in Q1 2023; total revenue $9.1M, down from $24.5M.
MacroGenics Phase 2 TAMARACK safety data shows improved tolerability at lower vobra duo doses
Drug interruption rate 12.6% vs 58.5% at 12 weeks in Phase 1; discontinuation 5.3% vs 14.6%.
MacroGenics reports FY2023 net loss of $9.1M; cash $229.8M; vobra duo data at ASCO 2024
Net loss $9.1M vs $119.8M in 2022; revenue $58.7M (down 61% YoY) due to lower collaboration revenue.
MacroGenics Q3 net income $17.6M ($0.28 EPS); cash $256.4M; TAMARACK enrollment ahead of schedule
Net income $17.6M ($0.28 diluted EPS) vs net loss $24.8M in Q3 2022; revenue $10.4M down from $41.7M.
MacroGenics Q2 net income $57.5M on royalty gain; $50M TZIELD milestone from Sanofi
Net income of $57.5M ($0.92 diluted EPS) vs net loss of $41.3M a year ago; driven by $100.9M gain on royalty monetization.
MacroGenics reports Q1 net loss $38M; cash runway through 2025 on $270M non-dilutive funding
Net loss of $38.0M ($0.61 loss per share) vs. $66.4M loss year ago; revenue $24.5M (up 121% YoY).
Net loss $119.8M ($1.95/share) vs $202.1M in 2021; revenue $151.9M (up 96% YoY).
MacroGenics sells TZIELD royalty to DRI for up to $200M; $100M upfront
Upfront payment of $100M for single-digit royalty on global net sales of TZIELD.
MacroGenics reports preliminary Phase 1 lorigerlimab data; 28.6% PSA50 in mCRPC
12 of 42 mCRPC patients (28.6%) achieved ≥50% PSA reduction; 9 of 42 (21.4%) achieved ≥90% PSA reduction.
MacroGenics earns $60M milestone from Provention on FDA approval of teplizumab
FDA approved teplizumab BLA for type 1 diabetes; MacroGenics receives $60M milestone from Provention.
MacroGenics Q3 net loss narrows to $24.8M; receives $60M Gilead upfront; cash runway into mid-2024
Q3 total revenue $41.7M (up from $15.7M YoY) including $30M Incyte milestone and $4.4M MARGENZA sales.
MacroGenics and Gilead sign $60M upfront option deal for MGD024 and two bispecific programs
Upfront $60M from Gilead; potential milestones up to $1.7B for MGD024 and two research programs.
MacroGenics Q2 net loss $41.3M; cuts 15% workforce, extends cash runway to 2024
Net loss $41.3M vs $39.9M YoY; cash $133.7M at June 30, plus $34.5M in July payments from partners.
Phase 2 study CP-MGA271-06 closed due to 7 fatal hemorrhagic events among 62 SCCHN patients.
On July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”) of her decision to resign from the Board, effective September 1, 2026.
On November 18, 2024, Ms. Lynn Cilinski notified MacroGenics, Inc. (the “ Company ”) of her intention to retire from her position as Vice President, Controller, Treasurer and Principal Accounting Officer, effective January 2, 2025
On November 19, 2024, the Board appointed Beth Smith as the Company’s Vice President, Controller, Treasurer and Principal Accounting Officer, effective as of the Effective Date.
On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of MacroGenics, Inc. (the “ Company ”) and the Company entered into a separation and consulting agreement, dated October 25, 2024 (the “ Separation Agreement ”), which provides for the terms of Dr. Koenig’s separation from employment, effective February 28, 2025
On January 3, 2023, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Meenu Chhabra Karson to serve as a director on the Board, effective January 3, 2023 (the “Effective Date”).
On December 19, 2022, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Margaret Liu, M.D. to serve as a director on the Board, effective January 3, 2023
who served in such position until his term as a director expired on May 19, 2022 upon the conclusion of the 2022 Annual Meeting of Stockholders
approved the appointment of William K. Heiden to serve as a director on the Board, effective immediately.
Mr. Heiden has been appointed to serve as non-executive Chair of the Board, effective immediately, replacing Mr. Paulo Costa
replacing Mr. Paulo Costa, who served in such position until his term as a director expired on May 19, 2022
On January 5, 2022 , Mr. Kenneth Galbraith, a member of the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”), notified the Board of his decision to resign from the Board, effective immediately.
On September 23, 2021, Mr. Paulo Costa, a member of the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”), notified the Board that he will not stand for reelection as a director of the Company upon expiration of his current term.
Max materiality 0.85 · Median 0.70 · Most common event other_material